Stock Scorecard
Stock Summary for Boston Scientific Corp (BSX) - $62.82 as of 4/6/2026 1:15:45 PM EST
Total Score
9 out of 30
Safety Score
62 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BSX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BSX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BSX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BSX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BSX (62 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for BSX
Financial Details for BSX
Company Overview |
|
|---|---|
| Ticker | BSX |
| Company Name | Boston Scientific Corp |
| Country | USA |
| Description | Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | 4/22/2026 |
Stock Price History |
|
| Last Day Price | 62.82 |
| Price 4 Years Ago | 46.27 |
| Last Day Price Updated | 4/6/2026 1:15:45 PM EST |
| Last Day Volume | 13,895,817 |
| Average Daily Volume | 14,910,933 |
| 52-Week High | 109.50 |
| 52-Week Low | 61.25 |
| Last Price to 52 Week Low | 2.56% |
Valuation Measures |
|
| Trailing PE | 32.38 |
| Industry PE | 42.15 |
| Sector PE | 65.47 |
| 5-Year Average PE | 24.30 |
| Free Cash Flow Ratio | 45.52 |
| Industry Free Cash Flow Ratio | 24.58 |
| Sector Free Cash Flow Ratio | 27.44 |
| Current Ratio Most Recent Quarter | 1.62 |
| Total Cash Per Share | 1.38 |
| Book Value Per Share Most Recent Quarter | 16.34 |
| Price to Book Ratio | 3.85 |
| Industry Price to Book Ratio | 4.22 |
| Sector Price to Book Ratio | 36.09 |
| Price to Sales Ratio Twelve Trailing Months | 4.65 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 4.98 |
| Analyst Buy Ratings | 24 |
| Analyst Strong Buy Ratings | 10 |
Share Statistics |
|
| Total Shares Outstanding | 1,486,175,000 |
| Market Capitalization | 93,361,513,500 |
| Institutional Ownership | 95.01% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.94% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 18.50% |
| Annual Earnings Growth | 55.66% |
| Reported EPS 12 Trailing Months | 1.94 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 3.05 |
| Net Income Twelve Trailing Months | 2,890,000,000 |
| Net Income Past Year | 2,886,000,000 |
| Net Income Prior Year | 1,854,000,000 |
| Quarterly Revenue Growth YOY | 15.90% |
| 5-Year Revenue Growth | 15.16% |
| Operating Margin Twelve Trailing Months | 19.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 2,045,000,000 |
| Total Cash Past Year | 2,045,000,000 |
| Total Cash Prior Year | 414,000,000 |
| Net Cash Position Most Recent Quarter | -9,092,000,000 |
| Net Cash Position Past Year | -9,092,000,000 |
| Long Term Debt Past Year | 11,137,000,000 |
| Long Term Debt Prior Year | 8,842,000,000 |
| Total Debt Most Recent Quarter | 11,137,000,000 |
| Equity to Debt Ratio Past Year | 0.69 |
| Equity to Debt Ratio Most Recent Quarter | 0.69 |
| Total Stockholder Equity Past Year | 24,233,000,000 |
| Total Stockholder Equity Prior Year | 21,770,000,000 |
| Total Stockholder Equity Most Recent Quarter | 24,233,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 3,625,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 2.44 |
| Free Cash Flow Past Year | 3,658,000,000 |
| Free Cash Flow Prior Year | 2,645,000,000 |
Options |
|
| Put/Call Ratio | 0.04 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -3.25 |
| MACD Signal | -2.90 |
| 20-Day Bollinger Lower Band | 59.93 |
| 20-Day Bollinger Middle Band | 84.55 |
| 20-Day Bollinger Upper Band | 109.18 |
| Beta | 0.78 |
| RSI | 22.66 |
| 50-Day SMA | 95.90 |
| 150-Day SMA | 80.01 |
| 200-Day SMA | 71.01 |
System |
|
| Modified | 4/6/2026 7:03:13 PM EST |